NeOnc Technologies Holdings is trading at $3.54, up 7.27% in pre-market after Roth/MKM initiated coverage on September 24, 2026, with a Buy rating and a $20 price target.

  • The coverage followed recent brain-cancer pipeline developments; the company-specific analyst action appears more directly relevant to the move than broader market gains.
  • Recent closes remained volatile, including a 14.05% gain on September 17.